| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:Dobra klinična praksa za raziskovalce, ki izvajajo klinična preskušanja zdravil
Authors:ID Tivadar, Andrijana (Author)
Files:.pdf Dobra_klinicna_praksa-Tivadar-2023.pdf (5,86 MB)
MD5: F9590BB8547D4599F47120D79C799C7A
 
URL https://journals.um.si/index.php/anali-pazu/article/view/3289
 
Language:Slovenian
Work type:Scientific work
Typology:1.01 - Original Scientific Article
Organization:UZUM - University of Maribor Press
Abstract:Razvoj zdravila je dolgotrajen in drag proces. Preden zdravilo dobi ustrezno dovoljenje za promet, je potrebno poleg njegove kakovosti dokazati tudi njegovo učinkovitost in varnost. Za dokazovanje učinkovitost in varnost zdravila so nujna klinična preskušanja. Klinično preskušanje zdravila je raziskava na zdravih posameznikih in pacientih, pri kateri je potrebno upoštevati načela dobre klinične prakse (GCP; Good clinical practice). Skladnost s tem standardom daje javno zagotovilo, da so pravice, varnost in dobrobit udeležencev v preskušanju zaščiteni ter da so podatki kliničnih preskušanj verodostojni. V kliničnem preskušanju zdravila sodelujejo raziskovalci, sponzorji in udeleženci. V prispevku se osredotočamo na raziskovalca v kliničnem preskušanju zdravila, ki mora dobro poznati načela GCP, da lahko svoje obveznosti in odgovornosti tudi upošteva. S prikazom primerov ugotovljenih pomanjkljivosti med inšpekcijo na mestu preskušanja (pri raziskovalcu) želimo raziskovalcem pomagati pri doseganju skladnosti z dobro klinično prakso.
Keywords:klinično preskušanje zdravila, dobra klinična praksa (GCP), raziskovalec, mesto preskušanja, inšpekcija
Publication status:Published
Publication version:Version of Record
Submitted for review:01.03.2023
Publication date:07.11.2023
Place of publishing:Maribor
Publisher:Univerza v Mariboru, Univerzitetna založba
Year of publishing:2023
Number of pages:17
Numbering:Letn.13, št.2
PID:20.500.12556/DKUM-97256 New window
UDC:615.07(497.4)
ISSN on article:2820-364X
COBISS.SI-ID:187898115 New window
DOI:10.18690/analipazu.13.2.17-33.2023 New window
Publication date in DKUM:25.02.2026
Views:150
Downloads:3
Metadata:XML DC-XML DC-RDF
Categories:Misc.
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share



Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Anali PAZU
Publisher:Združenje Pomurska akademsko znanstvena unija, Združenje Pomurska akademsko znanstvena unija, Univerzitetna založba Univerze v Mariboru
ISSN:2232-416X
COBISS.SI-ID:257553152 New window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:English
Title:Good Clinical Practice for Investigators Conducting Clinical Trials
Abstract:Drug development is a long and expensive process. Before a particular drug receives the appropriate marketing authorization, it is necessary to prove its efficacy and safety in addition to its quality. Clinical trials are necessary to prove the effectiveness and safety of the drug. A clinical trial of a drug is research conducted on healthy individuals and patients, in which the principles of good clinical practice (GCP) must be followed. Compliance with this standard provides public assurance that the rights, safety and wellbeing of trial subjects are protected and that clinical-trial data are credible. A clinical trial of a drug involves investigators, sponsors, and participants. In this paper, we focus on the investigator in the clinical trial of a drug, who must be well aware of the principles of GCP in order to be able to comply with his obligations and responsibilities. By showing examples of deficiencies identified during clinical trial site inspection (at the investigator), we aim to help investigators to achieve compliance with good clinical practice.
Keywords:clinical drug trial, good clinical practice, investigator, clinical trial site, inspection


Collection

This document is a part of these collections:
  1. Anali PAZU

Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica